Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database

被引：0
作者：
Stephanie H. Read
Nadia Quignot
Raissa Kapso-Kapnang
Erin Comerford
Ying Zheng
Corona Gainford
Medha Sasane
Anne-Lise Vataire
Laure Delzongle
Francois-Clement Bidard
机构：
[1] Certara UK Limited,Department of Medical Oncology
[2] Certara France,undefined
[3] Sanofi,undefined
[4] Sanofi,undefined
[5] Institut Curie,undefined
[6] Université Versailles Saint-Quentin,undefined
[7] Université Paris-Saclay,undefined
来源：
Breast Cancer Research and Treatment | 2024年 / 204卷
关键词：
Hormone receptor negative; Metastatic breast cancer; Endocrine therapy; Cyclin-dependent kinase 4/6 inhibitor; Real-world evidence; SNDS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：579 / 588
页数：9
相关论文
共 50 条
[31]   Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS study [J].
Mycock, Katie ;
Zhan, Lin ;
Hart, Kieran ;
Taylor-Stokes, Gavin ;
Milligan, Gary ;
Atkinson, Christian ;
Mitra, Debanjali .
CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 32
[32]   Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2-advanced or metastatic breast cancer in China [J].
Jia, Caifeng ;
Zhang, Sen ;
Wang, Jie ;
Feng, Bing ;
Shi, Fenghao ;
Wang, Meiqi ;
Li, Sainan ;
Xu, Hao ;
Wang, Mingxia .
SCIENTIFIC REPORTS, 2025, 15 (01)
[33]   Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer [J].
Wood, Robert ;
Mitra, Debanjali ;
de Courcy, Jonathan ;
Iyer, Shrividya .
CLINICAL THERAPEUTICS, 2017, 39 (08) :1719-1728
[34]   Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2-breast cancer: an umbrella review [J].
Pu, Dongqing ;
Xu, Debo ;
Wu, Yue ;
Chen, Hanhan ;
Shi, Guangxi ;
Feng, Dandan ;
Zhang, Mengdi ;
Liu, Zhiyong ;
Li, Jingwei .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (01)
[35]   CDK4/6 inhibitors in advanced HR+/HER2-breast cancer - a multicenter real world data analysis [J].
Mueller, C. ;
Kiver, V ;
Solomayer, E-F ;
Wagenpfeil, G. ;
Neeb, C. ;
Blohmer, J. U. ;
Abramian, A., V ;
Maass, N. ;
Schuetz, F. ;
Kolberg-Liedtke, C. ;
Ralser, D. J. ;
Rambow, A-C .
BREAST CARE, 2023, 18 (01) :31-41
[36]   Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy [J].
O'Connor, Thomas N. ;
Schultz, Emily ;
Wang, Jianxin ;
O'Connor, Tracey ;
Levine, Ellis ;
Knudsen, Erik S. ;
Witkiewicz, Agnieszka K. .
CANCERS, 2024, 16 (09)
[37]   Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2-advanced/metastatic breast cancer: updated systematic review [J].
Harbeck, Nadia ;
Brufsky, Adam ;
Rose, Chloe Grace ;
Korytowsky, Beata ;
Chen, Connie ;
Tantakoun, Krista ;
Jazexhi, Endri ;
Nguyen, Do Hoang Vien ;
Bartlett, Meaghan ;
Samjoo, Imtiaz A. ;
Pluard, Timothy .
FRONTIERS IN ONCOLOGY, 2025, 15
[38]   Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy [J].
Sottotetti, Federico ;
Tagliaferri, Barbara ;
Rizzo, Gianpiero ;
Palumbo, Raffaella ;
Chessa, Giulia ;
Raso, Chiara ;
Perrone, Lorenzo ;
Malovini, Alberto ;
Tibollo, Valentina ;
Locati, Laura Deborah ;
Pedrazzoli, Paolo ;
Lasagna, Angioletta .
DRUGS IN CONTEXT, 2025, 14
[39]   Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: A chart review study in the US [J].
Xie J. ;
Hao Y. ;
Li N. ;
Lin P.L. ;
Ohashi E. ;
Koo V. ;
Wu E.Q. .
Experimental Hematology & Oncology, 4 (1)
[40]   CDK4/6 inhibitors in HR+/HER2-advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies [J].
Harbeck, Nadia ;
Bartlett, Meaghan ;
Spurden, Dean ;
Hooper, Becky ;
Zhan, Lin ;
Rosta, Emily ;
Cameron, Chris ;
Mitra, Debanjali ;
Zhou, Anna .
FUTURE ONCOLOGY, 2021, 17 (16) :2107-2122
12345